|
1
|
Gandellini P, Doldi V and Zaffaroni N:
microRNAs as players and signals in the metastatic cascade:
Implications for the development of novel anti-metastatic
therapies. Semin Cancer Biol. 44:132–140. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou W, Wang S, Ying Y, Zhou R and Mao P:
miR-196b/miR-1290 participate in the antitumor effect of
resveratrol via regulation of IGFBP3 expression in acute
lymphoblastic leukemia. Oncol Rep. 37:1075–1083. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gartel AL and Kandel ES: miRNAs: Little
known mediators of oncogenesis. Semin Cancer Biol. 18:103–110.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kai K, Dittmar RL and Sen S: Secretory
microRNAs as biomarkers of cancer. Semin Cell Dev Biol. 78:22–36.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nambara S and Mimori K: MicroRNA in
various aspects of cancer development. Gan To Kagaku Ryoho.
44:362–366. 2017.(In Japanese). PubMed/NCBI
|
|
7
|
Fang YX and Gao WQ: Roles of microRNAs
during prostatic tumorigenesis and tumor progression. Oncogene.
33:135–147. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su SF, Chang YW, Andreu-Vieyra C, Fang JY,
Yang Z, Han B, Lee AS and Liang G: miR-30d, miR-181a and
miR-199a-5p cooperatively suppress the endoplasmic reticulum
chaperone and signaling regulator GRP78 in cancer. Oncogene.
32:4694–4701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Zhu J, Zhang YH, Chen YS, Ding LL,
Kensler TW and Chen JG: Lung cancer in a rural area of China: Rapid
rise in incidence and poor improvement in survival. Asian Pac J
Cancer Prev. 16:7295–7302. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamano S, Gi M, Tago Y, Doi K, Okada S,
Hirayama Y, Tachibana H, Ishii N, Fujioka M, Tatsumi K and
Wanibuchi H: Role of deltaNp63posCD44vpos cells in the development
of N-nitroso-tris-chloroethylurea-induced peripheral-type mouse
lung squamous cell carcinomas. Cancer Sci. 107:123–132. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YC, Zhou Q and Wu YL: Emerging
challenges of advanced squamous cell lung cancer. ESMO Open.
1:e0001292016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Funai K, Yokose T, Ishii G, Araki K,
Yoshida J, Nishimura M, Nagai K, Nishiwaki Y and Ochiai A:
Clinicopathologic characteristics of peripheral squamous cell
carcinoma of the lung. Am J Surg Pathol. 27:978–984. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Griffiths-Jones S, Saini HK, Van Dongen S
and Enright AJ: Enrigh: Tools for microRNA genomics. Nucleic Acids
Res. 36:D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and
Qian B: MiR-195 suppresses non-small cell lung cancer by targeting
CHEK1. Oncotarget. 6:9445–9456. 2015.PubMed/NCBI
|
|
16
|
Han K, Chen X, Bian N, Ma B, Yang T, Cai
C, Fan Q, Zhou Y and Zhao TB: MicroRNA profiling identifies MiR-195
suppresses osteosarcoma cell metastasis by targeting CCND1.
Oncotarget. 6:8875–8889. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang R, Zhao N, Li S, Fang JH, Chen MX,
Yang J, Jia WH, Yuan Y and Zhuang SM: MicroRNA-195 suppresses
angiogenesis and metastasis of hepatocellular carcinoma by
inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology.
58:642–653. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cai C, Chen QB, Han ZD, Zhang YQ, He HC,
Chen JH, Chen YR, Yang SB, Wu YD, Zeng YR, et al: miR-195 inhibits
tumor progression by targeting RPS6KB1 in human prostate cancer.
Clin Cancer Res. 21:4922–4934. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu H, Hu YW, Zhao JY, Hu XM, Li SF, Wang
YC, Gao JJ, Sha YH, Kang CM, Lin L, et al: MicroRNA-195-5p acts as
an anti-oncogene by targeting PHF19 in hepatocellular carcinoma.
Oncol Rep. 34:175–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai H, Zhao H, Tang J and Wu H: Serum
miR-195 is a diagnostic and prognostic marker for osteosarcoma. J
Surg Res. 194:505–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Igglezou M, Vareli K, Georgiou GK, Sainis
I and Briasoulis E: Kinetics of circulating levels of miR-195,
miR-155 and miR-21 in patients with breast cancer undergoing
mastectomy. Anticancer Res. 34:7443–7447. 2014.PubMed/NCBI
|
|
23
|
Lin L, Huang Y and Gong W: Inhibition of
miR-92b suppresses nonsmall cell lung cancer cells growth and
motility by targeting RECK. Mol Cell Biochem. 387:171–176. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishikawa R, Goto Y, Kojima S, Enokida H,
Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y,
et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration
and invasion via targeting LAMC1 in prostate cancer. Int J Oncol.
45:401–410. 2014. View Article : Google Scholar : PubMed/NCBI
|
